Health-care companies were more or less flat as Novo Nordisk's robust obesity-drug sales offset weakness elsewhere.
Shares of Novo Nordisk soared after the Danish drug giant said sales of Biogen is pulling the plug on its ill-fated Alzheimer's disease drug Aduhelm, shifting resources to the development of Leqembi, a separate Alzheimer's treatment it 's developing with Aduhelm partner Esai.
Novartis shares dropped after the Swiss pharmaceutical company reported fourth-quarter earnings and sales that missed consensus expectations.
Shares of Boston Scientific rallied after the stent-maker posted stronger-than-anticipated fourth-quarter sales and forecast more growth ahead. Health-insurance giant Cigna agreed to sell its Medicare business to rival Health Care Service for $3.3 billion.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
01-31-24 1727ET